85
Participants
Start Date
October 19, 2017
Primary Completion Date
December 31, 2021
Study Completion Date
December 31, 2022
Nivolumab
"Dosage Form: Nivolumab BMS-936558-01 Solution for Injection Potency: 100 mg (10 mg/mL) Primary Packaging: 10 mL vial Appearance: Clear to opalescent colourless to pale yellow liquid. May contain particles.~Storage Condition: 2 to 8°C. Protect from light and freezing."
Ipilimumab
Dosage Form: Ipilimumab Solution for Injection Potency: 200 mg (5 mg/mL) Primary Packaging: 40 mL vial Appearance: Clear, colourless to pale yellow liquid. May contain particles. Storage Condition: 2 to 8°C. Protect from light and freezing.
St Vincents Hospital, Darlinghurst
Prince of Wales Hospital, Randwick
Chris O'Brien Lifehouse, Camperdown
Northern Cancer Institute, Frenchs Forest
Westmead Hospital, Westmead
St. George Hospital, Kogarah
Calvary Mater Newcastle, Newcastle
Tamworth Hospital - North West Cancer Centre, Tamworth
Port Macquarie Base Hospital, Port Macquarie
Border Medical Oncology, Albury
Campbelltown Hospital, Campbelltown
Box Hill Hospital - Eastern Health, Box Hill
Monash Medical Centre, Clayton
Ballarat Oncology & Haematology Services, Ballarat
Royal Brisbane & Women's Hospital, Brisbane
Sunshine Coast University Hospital, Birtinya
Flinders Medical Centre, Adelaide
Ashford Cancer Centre, Adelaide
Fiona Stanley Hospital, Murdoch
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
OTHER